UNSPSC 51183604: Exenatide synthetic

This classification denotes an anti-diabetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9P1872D4OL. European Medicines Agency schedules Exenatide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21818. Exenatide synthetic generally arises in the molecular formula C184H282N50O60S. The term 'exenatide synthetic' is a U.S. FDA Orange Book designation. Most nations, for tariff and trade purposes, schedule exenatide synthetic under HS 29332990. SMILES:.

UNSPSC 51183604 Exenatide synthetic is a Commodity code representing diabetes-management pharmaceuticals that state and local governments procure through cooperative purchasing agreements and multi-source generic drug programs. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, uses this code as part of broader pharmaceutical procurement frameworks that bundle specific active pharmaceutical ingredients—including exenatide formulations—with hundreds of other generic and branded medications and over-the-counter products. State and local issuing bodies acquiring under this code typically do so through cooperative purchasing vehicles rather than individual agency RFPs, allowing participating jurisdictions to leverage volume discounts and simplified vendor management across multiple states. MMCAP participants include state health agencies, local government facilities, and subordinate purchasing offices across Minnesota, Oregon, and other member states, which collectively negotiate pricing and supply agreements with pharmaceutical manufacturers and authorized wholesalers.

The most recent opportunity under this code is MMCAP's January 2026 RFP for Generic Multi Source Pharmaceuticals and OTC Products (Solicitation S1070000015802, due March 26, 2026), which seeks manufacturers to supply products including exenatide formulations through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC. Vendors must submit detailed product information indexed to National Drug Codes, comply with current Good Manufacturing Practices and the Drug Supply Chain Security Act, maintain contractual relationships with at least two authorized wholesalers with chargeback systems, and accept pricing in formats such as flat price, net price, or WAC-minus structures. The contract runs two years for new responders with optional extensions, effective July 1, 2026, and evaluation emphasizes price competitiveness (75 percent weight), with secondary points for fixed pricing, administrative compliance, EDI capability, and acceptance of a 3 percent administrative fee. No specific set-aside designations are identified in the solicitation materials, and award structure remains at MMCAP's discretion as sole, dual, or multi-awards based on therapeutic and patient-safety considerations.